News

As external pressures such as government regulations continue to mount and alter the approach to deal making in the healthcare sector, there are five things health services executives should watch.

Where do the capabilities of healthcare technology end and the need for the human hand begin to deliver top value for managed care executives?

Several recent studies explore how weight loss surgery impacts diabetes patient care.

Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.

FDA’s approval of a new biosimilar-the third FDA-approved biosimilar-stands to save the US healthcare system millions of dollars.

Technology in pharmacy is leading to improved safety, accountability, and efficiency.

The proposed HHS Notice of Benefit and Payment Parameters for 2018 indicates CMS is focusing on refining the risk adjustment model to better compensate plans.

The opioid crisis in the U.S. is a multidimensional problem requiring a multistakeholder solution.

This model, touted as “next-generation,” combines retail and specialty and mail services and PBM along with immediate care clinics.

CMS’ Quality Payment Program (QPP) introduced in the Medicare Access and CHIP Reauthorization Act (MACRA) has created a seismic effect across provider organizations.

Managed Healthcare Executive asked industry experts to share their favorite mobile apps for healthcare. Here’s 13 of their top picks.

Managed Healthcare Executive recently invited a panel of experts representing different sectors of the healthcare industry to explore specialty pharmaceutical challenges and identify potential solutions.

Learning how to appreciate the value of experiences is key for these execs, who share their biggest career mistake was and how they learned from it.

Despite offering a generic version of its EpiPen, Mylan has been unable to curb the backlash that began in late August over the cost of its epinephrine injection.

FDA recently approved the only oxycodone with oral abuse-deterrent features.

Healthcare spending for people with diabetes rose nearly 6% in 2014, according to a new study. Find out what contributed to the rise.

UK study: Diabetes increases risk of heart attack death. Here are the surprising details.

There are promising developments in the pipeline for patients with treatment-resistant depression.

Managed Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.

Rising drug costs are a big problem for all healthcare systems in the U.S. Here’s how three hospitals are addressing the problem.

After protests by patients, parents and Congressional representatives, Mylan said it would offer discounts on its epinephrine EpiPen Auto-Injector treatment to stop allergic reactions.

FDA recently granted Breakthrough Therapy Designation for esketamine (Janssen Research & Development), an investigational medication to treat major depressive disorder with imminent risk for suicide.

As health plans work to develop and price products for the 2017 open-enrollment cycle-beginning November 1, 2016, it looks like some premiums are set to rise substantially.

Expert: Expectations are high that biosimilars can control overall biologic cost growth.

CMS just released the first Comprehensive Care for Joint Replacement (CJR) data feed. Find out what the preliminary results show.

Here’s what to expect from Blue Shield of California’s four-day closure over Obamacare losses.

CMS expands bundle payment programs by adding cardiac care. Here’s how you can contribute to providers’ success.

PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study.

As Aetna bows out of health insurance exchanges, more questions about viability are cropping up. Find out which other plans are exiting the health insurance exchanges.

FDA recently approved granisetron (Sustol, Heron Therapeutics) extended-release injection to prevent nausea and vomiting associated with repeat courses of chemotherapy.